SCHEMBL453612

SCHEMBL453612

Cc1ccc(-c2cc(C(=O)OC(C)(C)C)cn3c(-c4ccccc4)nnc23)nc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD9 Q9H8M2 1/20 0.37
GRM5 P41594 1/20 0.37
HPGDS O60760 1/20 0.35
GABRA1 P14867 3/20 0.34
GABRG2 P18507 3/20 0.34
GABRB3 P28472 3/20 0.34
GABRA5 P31644 3/20 0.34
GABRA3 P34903 3/20 0.34
GABRA2 P47869 3/20 0.34
GABRA6 Q16445 1/20 0.34
P2RX3 P56373 6/20 0.34
P2RX2 Q9UBL9 6/20 0.34
PDE10A Q9Y233 2/20 0.34
GABRA4 P48169 1/20 0.33
PDE2A O00408 2/20 0.33
ALDH1A1 P00352 2/20 0.33
PDK2 Q15119 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL455880 0.87 BRD9 (0.38) BRD9GABRA1GABRG2GABRB3GABRA5
SCHEMBL463333 0.87 GRM5 (0.41) GRM5GABRA1GABRG2GABRB3GABRA5
SCHEMBL454107 0.79 BRD9 (0.40) BRD9HPGDSGABRA1GABRG2GABRB3
SCHEMBL28664378 0.74 CYP3A4 (0.47) HPGDSGABRA1GABRG2GABRB3GABRA5
SCHEMBL454669 0.73 SQOR (0.41) GRM5ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL455326 0.72 NR1H2 (0.41) ALDH1A1KDM4EGAALMNA
SCHEMBL452183 0.69 TACR3 (0.40) PDE10APDE2AALDH1A1NPC1RAB9A
SCHEMBL3067384 0.67 NR1I2 (0.41) P2RX3P2RX2RAB9A
SCHEMBL3053335 0.65 BAZ2B (0.44) P2RX3P2RX2
SCHEMBL3070659 0.64 GPR119 (0.35) HPGDSP2RX3P2RX2ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9238647-B2 P2X3 receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2016-01-19 US disclosed
EP-2410857-B1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME (US) 2014-01-29 EP disclosed
US-20120064181-A1 P2X3 Receptor Antagonists for Treatment of Pain MERCK SHARP & DOHME LLC 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064181-A1 P2X3 Receptor Antagonists for Treatment of Pain P2RX3, P2RX1, P2RX2 BRD9 3162/4885GRM5 132/4885HPGDS 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.